RA Capital's sustained accumulation at $8.95–$9.99 suggests a strong conviction in ARTV's near-term value. Traders should watch for upcoming clinical data readouts or partnership announcements that could catalyze the stock. The prior cluster of $1.0M in buys on July 23–24 amplifies this signal — consider building a position with a stop below the $8.95 cluster low.
Price Chart
Executive Summary
RA Capital Management, a 10% owner and director, made a series of open-market purchases totaling ~$3.07M over 7 days (July 17–24), with the bulk at $9.55–$9.99 per share. This is a conviction buy from a sophisticated healthcare investor, representing ~1.2% of ARTV's $255M market cap, and follows a prior cluster of $1.0M in RA Capital buys on July 23–24. The insider's willingness to increase exposure at these levels, combined with strong historical T+20 performance on prior ARTV insider-buy reports (+4.77% avg), signals confidence in upcoming catalysts or undervaluation.
Key Financial Metrics
Key Facts
- RA Capital Management (Director, 10% Owner) purchased ~313.8K shares total across 5 trades from July 17–24, 2026
- Total purchase value: ~$3.07M, representing ~1.2% of ARTV's $255M market cap
- Weighted average purchase price: ~$9.78 per share
- Prior 30-day insider activity: 9 buys totaling $4.7M, indicating sustained insider accumulation
- Historical reports on ARTV insider buys show avg T+20 return of +4.77% with 67% win rate
Financial Impact
RA Capital spent ~$3.07M to acquire ~313.8K shares, ~1.2% of market cap
Risk Factors
- Biotech clinical-stage risk — no approved products; pipeline setbacks could erase value
- Insider buying does not guarantee near-term catalysts; stock may drift without news
- RA Capital is a large holder — future sales could pressure shares if thesis changes
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| INSIDER-BUY Data (Synthetic) | 0001231919-26-000808 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 20d ago | 8-K | $10.14 $8.91 | ▼ −12.13% | ▼ −11.67% | $6.86 (−32.35%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▼ −3.43% | ▼ −2.83% | $6.86 (−36.42%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▼ −3.43% | ▼ −2.83% | $6.86 (−36.42%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▼ −3.43% | ▼ −2.83% | $6.86 (−36.42%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▼ −3.43% | ▼ −2.83% | $6.86 (−36.42%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▲ +3.43% | ▲ +2.83% | $6.86 (+36.42%) |
Sep 4, 2026 28d ago | Insider Cluster | $11.19 $10.88 | ▼ −2.77% | ▼ −2.22% | $6.86 (−38.70%) |
Aug 15, 2026 6w ago | Institutional Cluster | $11.74 $11.68 | ▼ −0.51% | ▲ +0.16% | $6.86 (−41.57%) |
Jul 31, 2026 8w ago | Insider Buy | $10.76 $11.07 | ▲ +2.88% | ▲ +1.08% | $6.86 (−36.25%) |
Jul 28, 2026 9w ago | Insider Buy | $10.53 $10.02 | ▼ −4.84% | ▼ −3.30% | $6.86 (−34.85%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access